Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate – Pharmaceutical Technology

Six months after winning fast track status for multiple sclerosis, Kyverna Therapeutics KYV-101 has secured another US Food and Drug Administration (FDA) designation; this time, a regenerative medicine advanced therapy (RMAT) tag for the treatment of stiff-person syndrome.

An RMAT designation includes those benefits included in the fast track and breakthrough therapy pathways such as a priority review, along with early and enhanced FDA interactions. The RMAT tag also permits the use of surrogate endpoints in clinical trials studying the therapy, which can lead to accelerated approval.

Shares in the US biotech rose 9.5% at market open compared to a pre-announcement 15 July market close. Kyverna has a market cap of $427m.

Kyvernas KYV-101 is a CD19 chimeric antigen receptor (CAR)-T cell therapy designed for B cell-driven autoimmune disorders. It is currently being evaluated in a Phase II trial in patients with treatment-refractory stiff-person syndrome. The study, named KYSA-8, received the FDA greenlight last month.

The RMAT applications success was based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named patient treatment option, according to a 16 July press release.

Kyverna has not revealed further information about the US trial, with the biotechs CEO Peter Maag saying we are eager to begin generating data.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

Country * UK USA Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Cte d"Ivoire Croatia Cuba Curaao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Runion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

Stiff-person syndrome is a progressive autoimmune disorder that causes muscle stiffness and spasms in the torso and limbs. Many patients can break bones from falling as they lack the necessary muscle reflexes for correction. It is not known what causes the disease.

Kyverna is considering cell therapy treatments beyond blood cancers, the space in which many CAR-T treatments are currently approved to treat. KVY-101 is being evaluated in sponsored Phase I/II and Phase II trials in the US and Germany in indications such as refractory lupus nephritis (NCT05938725), multiple sclerosis, and myasthenia gravis. The biotech reported positive Phase I results for the cell therapy in multiple sclerosis patients in April this year, the indication for which the drug has fast track status from the FDA.

In total, Kyverna says that 50 patients with cancer or autoimmune conditions have been treated with KYV-101 so far.

Kyverna went public earlier this year, raising $319m in the process. The initial public offering (IPO), which was larger than expected, saw the company sell 14.5 million shares for $22 each.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported byCytiva.

Editorialcontent is independently produced and follows thehigheststandardsof journalistic integrity. Topic sponsors are not involved in the creation ofeditorialcontent.

Give your business an edge with our leading industry insights.

More:
Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate - Pharmaceutical Technology